To determine the induction of tumor antigen-specific CD8 T cells by Ab-retargeting, we investigated whether DE1scFv-pSia therapy is able to trigger a specific CD8 T-cell response against the mutated neoantigen Adpgk-R304M by intracellular cytokine staining. The gene discussed is CD8A; the disease is neoplasm.